Director Rothenberg Mace purchased 20,000 shares at TNGX for $74,000 across 2 transactions as stock trades 72.0% below 52-week high
Rothenberg Mace, a director at Tango Therapeutics, executed 2 separate purchases totaling 20,000 shares for $74,000.00 on November 14 and November 18, 2024, at prices of $3.62 and $3.78 respectively, expanding his holdings by 177.8% from 11,250 shares to 31,250 shares. The purchases occur as TNGX trades at $3.60, representing a 72.0% decline from its 52-week high of $12.88 and a 51.7% decline over the preceding 30 days. The company remains unprofitable with a net income of $-29,167,000.00 over its most recent full fiscal year, though it achieved 46.9% annual revenue growth, presenting a tension between expanding topline performance and continued cash burn. This substantial accumulation by a director at a distressed valuation merits attention to whether it reflects insider confidence or execution constraints at the early-stage biotech stage.